Christian triumph, Christian tragedy : the theological context of Clarissa

The aim of this paper is to revisit some Iberian inscriptions from three sites of Teruel: a graffiti from San Antonio (Calaceite) that was recovered in Juan Cabré’s excavations and is preserved in the Archaeological Museum of Barcelona; a possible bilingual inscription from Azaila that was engraved on a pebble, wich is nowadays lost but presents a notable similarity with another inscribed pebble find in La Moleta dels Frares (Castellón); and, finally, two steles from La Iglesuela del Cid, where also are preserved a third Iberian inscription and a collection of Latin epigraphs.El objetivo de este artículo es revisar varias inscripciones ibéricas procedentes de tres yacimientos de la provincia de Teruel: un grafito grabado sobre un adobe de San Antonio de Calaceite, recuperado en las excavaciones de Juan Cabré y que se conserva en el Museo Arqueológico de Barcelona; una posible inscripción bilingüe de Azaila, incisa sobre un pequeño canto rodado, actualmente perdido y que presenta una notable similitud con otro descubierto en La Moleta dels Frares (Castellón); y, finalmente, dos estelas de La Iglesuela del Cid, reutilizadas como material de construcción en la ermita de Nuestra Señora del Cid, donde también se conservan una tercera inscripción ibérica y un conjunto de epígrafes latinos

Christian triumph, Christian tragedy The theological context of Clarissa

SIGLEAvailable from British Library Document Supply Centre- DSC:DXN058861 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016

The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the diagnosis and management of the full spectrum of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS-TEN overlap in adults during the acute phase of the disease.The document aims to:Offer an appraisal of all relevant literature up to February 2016, focusing on any key developments.Address important, practical clinical questions relating to the primary guideline objective, i.e. accurate diagnosis and identification of cases and suitable treatment.Provide guideline recommendations.Discuss areas of uncertainty, potential developments and future directions

Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries

Background: Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0–14 years) and adults (aged 15–99 years) diagnosed with a haematological malignancy during 2000–14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0–24 years). Methods: We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0–14 years), adolescents (15–19 years), and young adults (20–24 years). We categorised leukaemia subtypes according to the International Classification of Childhood Cancer (ICCC-3), updated with International Classification of Diseases for Oncology, third edition (ICD-O-3) codes. We estimated 5-year net survival by age and morphology, with 95% CIs, using the non-parametric Pohar-Perme estimator. To control for background mortality, we used life tables by country or region, single year of age, single calendar year and sex, and, where possible, by race or ethnicity. All-age survival estimates were standardised to the marginal distribution of young people with leukaemia included in the analysis. Findings: 164 563 young people were included in this analysis: 121 328 (73·7%) children, 22 963 (14·0%) adolescents, and 20 272 (12·3%) young adults. In 2010–14, the most common subtypes were lymphoid leukaemia (28 205 [68·2%] patients) and acute myeloid leukaemia (7863 [19·0%] patients). Age-standardised 5-year net survival in children, adolescents, and young adults for all leukaemias combined during 2010–14 varied widely, ranging from 46% in Mexico to more than 85% in Canada, Cyprus, Belgium, Denmark, Finland, and Australia. Individuals with lymphoid leukaemia had better age-standardised survival (from 43% in Ecuador to ≥80% in parts of Europe, North America, Oceania, and Asia) than those with acute myeloid leukaemia (from 32% in Peru to ≥70% in most high-income countries in Europe, North America, and Oceania). Throughout 2000–14, survival from all leukaemias combined remained consistently higher for children than adolescents and young adults, and minimal improvement was seen for adolescents and young adults in most countries. Interpretation: This study offers the first worldwide picture of population-based survival from leukaemia in children, adolescents, and young adults. Adolescents and young adults diagnosed with leukaemia continue to have lower survival than children. Trends in survival from leukaemia for adolescents and young adults are important indicators of the quality of cancer management in this age group